You are here
A selection of articles on Melanoma
Caputo E, Miceli R, Motti M, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero M, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto P.J Transl Med. 2014 Jul 31;12(1):216. [Epub ahead of print]
In this work it was explored the effect of a triple combination with BRAF and MEK inhibitors...
Sara Tomei, Davide Bedognetti, Valeria De Giorgi, Michele Sommariva, Sara Civini, Jennifer Reinboth, Muna Al Hashmi, Maria Libera Ascierto, Qiuzhen Liu, Ben D. Ayotte, Andrea Worschech, Lorenzo Uccellini, Paolo A. Ascierto, David Stroncek, Giuseppe PalmieOriginal Research Article Molecular Oncology, In Press, Uncorrected Proof, Available online 6 August 2014
The role of oncogenes BRAF and NRAS has been extensively described with regard to their ability to...
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
Maria Romina Girotti, Grazia Saturno, Paul Lorigan, Richard MaraisReview Article Molecular Oncology, In Press, Uncorrected Proof, Available online 15 August 2014
This is a review which comprehensively covers the enormous progress made in recent years in the treatment...
BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy
Andrew P. Barbour, Yue Hang Tang, Nicola Armour, Ken Dutton-Regester, Lutz Krause, Kelly A. Loffler, Duncan Lambie, Bryan Burmeister, Janine Thomas, B. Mark Smithers, Nicholas K. Hayward
European Journal of Cancer
This interesting work shows the data obtained from the analysis of a prospective database with Stage IIIA-C...
Diego M. Marzese, Jamie L. Huynh, Neal P. Kawas, Dave S.B. Hoon
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature
Giuseppe Lombardi, Anna Luisa Di Stefano, Patrizia Farina, Vittorina Zagonel, Emeline Tabouret
Cancer Treatment Reviews
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
Richard D. Carvajal, Michael K. Wong, John A. Thompson, Michael S. Gordon, Karl D. Lewis, Anna C. Pavlick, Jedd D. Wolchok, Patrick B. Rojas, Jonathan D. Schwartz, Agop Y. Bedikian
European Journal of Cancer
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells
Yukihiko Katoa, Ikuyo Yoshino, Chizu Egusa, Tatsuo Maeda, Roberto Pili, Ryoji TsuboiJournal of Dermatological Science, Available online 14 May 2014, Pages 986-997
This is a study that evaluates the efficacy of the association of Histone deacetylase (HDAC) inhibitor, MS-275,...
Joselin D. Tacastacas, Julie Bray, Yoon K. Cohen, Joshua Arbesman, Julian Kim, Henry B. Koon, Kord Honda, Kevin D. Cooper, Meg R. GerstenblithJournal of the American Academy of Dermatology, Available online 6 May 2014
This is a comprehensive review that provides a broad overview on the mucosal melanoma, starting with the...
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P.Lancet Oncol. 2014 May;15(6):620-30. Epub 2014 Apr 15.
The effectiveness of anti-angiogenic factors in the treatment of melanoma is currently the subject of many clinical...